Colorado small businesses are less likely to change health insurers for the upcoming year, even as they anticipate continued price increases, according to the second-annual Delta Dental of Colorado Small Business Survey.
Click here to read more
“We anticipate that operating losses will occur and substantially increase over the next several years as we expand discovery, research and development activities, including clinical development of our Tarmogen product candidates,” the company wrote in its earnings report.
In July, GlobeImmune – which is developing therapeutic drugs for pancreatic cancer and hepatitis B and C – went public, pricing its shares at $10 apiece and raising $17.3 million in gross proceeds.
The company’s shares have steadily declined since hitting a high point of $14.79 on July 11. They were trading at $8.62 by mid-afternoon Friday, down 7 percent from the previous day’s close.